Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Oncternal Therapeutics, Inc. (ONCT)
Last oncternal therapeutics, inc. earnings: 8/8 04:01 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitors; initial data readout expected in the second quarter of 2024 Encouraging response signal at initial dose level in our ongoing Phase 1/2 study for ONCT-808, our ROR1-targeting autologous CAR T cell therapy, for the treatment of patients with relapsed or refractory aggressive B-cell lymphoma, including patients that have failed prior CD19 CAR T treatment; clinical data update expected in mid-2024 Cash, cash equivalents and short-term investments totaled $34.3 million as of December 31, 2023; cash runway projected into 2025 Management to host webcast today at 5:00 pm ET SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2023 financial results. “We are encouraged by the pro
Show less
Read more
Impact Snapshot
Event Time:
ONCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONCT alerts
High impacting Oncternal Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ONCT
News
- Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer [Yahoo! Finance]Yahoo! Finance
- Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate CancerGlobeNewswire
- Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Oncternal Therapeutics, Inc. (NASDAQ: ONCT) had its price target lowered by analysts at HC Wainwright from $30.00 to $28.00. They now have a "buy" rating on the stock.MarketBeat
ONCT
Earnings
- 3/7/24 - Miss
ONCT
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- ONCT's page on the SEC website